天康生物(002100) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for the first nine months of 2023 reached ¥14,705,995,884.82, an increase of 14.13% compared to the same period last year[12]. - The net profit attributable to shareholders for Q3 2023 was -¥57,093,469.98, a decrease of 116.06% year-on-year[12]. - Total operating revenue for the third quarter of 2023 reached ¥14,705,995,884.82, an increase from ¥12,885,513,743.09 in the same period last year, representing a growth of approximately 14.1%[43]. - The company's net profit for the third quarter was not explicitly stated, but the total equity as of September 30, 2023, was ¥8,797,087,580.64, down from ¥9,664,970,773.09 year-over-year[42]. - Basic earnings per share for the third quarter were CNY -0.37, compared to CNY 0.19 in the same quarter last year[30]. Cash Flow and Investments - The net cash flow from operating activities for the first nine months of 2023 was ¥3,299,011,956.09, reflecting a 79.90% increase compared to the previous year[12]. - Cash inflow from operating activities totaled CNY 14,236,368,190.53, up from CNY 12,363,461,818.92, reflecting a growth of 15.1%[46]. - Cash outflow from operating activities increased slightly to CNY 10,937,356,234.44 from CNY 10,529,676,696.81, representing a rise of 3.9%[46]. - The cash flow from investment activities showed a net outflow of CNY 427,675,222.04, an improvement from a net outflow of CNY 777,460,915.19 in the previous period[46]. - The company received CNY 650,000,000.00 from the recovery of investments during the current period[46]. Assets and Liabilities - The company's total assets decreased by 14.17% to ¥16,616,785,831.78 compared to the end of the previous year[12]. - The company's total liabilities decreased from CNY 9.70 billion to CNY 7.82 billion, a reduction of about 19.4%[26]. - The total equity attributable to shareholders decreased from CNY 7.95 billion to CNY 7.15 billion, a decline of about 10.0%[26]. - The company's long-term borrowings decreased from CNY 3.13 billion to CNY 1.77 billion, a reduction of approximately 43.3%[26]. - The total amount of government subsidies recognized in the current period is CNY 22,823,428.50, compared to CNY 36,053,238.87 in the previous period[51]. Research and Development - Research and development expenses increased by 45.64% to ¥178,179,797.12 for the first nine months of 2023, indicating a significant investment in innovation[8]. - Research and development expenses for the third quarter amounted to ¥178,179,797.12, up from ¥122,345,021.87 in the same quarter last year, reflecting a significant increase of approximately 45.7%[43]. Inventory and Receivables - The company reported a 102.18% increase in accounts receivable, amounting to ¥801,535,970.88, due to a sales peak in its pharmaceutical and feed businesses[8]. - Inventory levels decreased to ¥3,235,000,195.84 from ¥6,039,231,841.92 year-over-year, indicating a reduction of approximately 46.6%[39]. Other Financial Metrics - The company experienced a 72.28% decline in investment income, totaling ¥3,557,400.48, due to a reduction in equity stakes[8]. - The company reported a financial loss from asset impairment of ¥49,364,048.98 in the third quarter, compared to a gain of ¥54,816,890.10 in the same period last year[43]. - The non-operating income and expenses resulted in a total of CNY 14,588,695.02 for the current period, significantly higher than CNY 7,625,754.10 in the previous period[51]. - The cash paid for taxes decreased slightly to CNY 133,291,915.14 from CNY 137,200,814.57, a decline of 2.9%[46].